WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007009589) USE OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF RAYNAUD'S PHENOMENON
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/009589    International Application No.:    PCT/EP2006/006501
Publication Date: 25.01.2007 International Filing Date: 04.07.2006
IPC:
A61K 31/194 (2006.01), A61K 31/506 (2006.01), A61K 31/5377 (2006.01), A61P 9/08 (2006.01)
Applicants: BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE) (For All Designated States Except US).
KRAHN, Thomas [DE/DE]; (DE) (For US Only).
STASCH, Johannes-Peter [DE/DE]; (DE) (For US Only).
WEIMANN, Gerrit [DE/DE]; (DE) (For US Only).
THIELEMANN, Wolfgang [DE/DE]; (DE) (For US Only)
Inventors: KRAHN, Thomas; (DE).
STASCH, Johannes-Peter; (DE).
WEIMANN, Gerrit; (DE).
THIELEMANN, Wolfgang; (DE)
Common
Representative:
BAYER HEALTHCARE AG; Law And Patents, Patents and Licensing, 51368 Leverkusen (DE)
Priority Data:
10 2005 033 370.2 16.07.2005 DE
10 2005 047 945.6 06.10.2005 DE
Title (DE) VERWENDUNG VON AKTIVATOREN DER LÖSLICHEN GUANYLATZYKLASE ZUR BEHANDLUNG VON RAYNAUD PHÄNOMENEN
(EN) USE OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF RAYNAUD'S PHENOMENON
(FR) UTILISATION D'ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE POUR TRAITER LES PHENOMENES DE RAYNAUD
Abstract: front page image
(DE)Die vorliegende Erfindung betrifft die Verwendung von Verbindungen der Formeln (I-VI) zur Herstellung eines Arzneimittels zur Behandlung von primärem und sekundärem Raynaud Phänomen.
(EN)The invention relates to the use of compounds of formulae (I-VI) for the production of a medicament for the treatment of primary and secondary Raynaud's phenomenon.
(FR)L'invention concerne l'utilisation de composés de formules (I-VI) pour produire un médicament destiné au traitement du phénomène de Raynaud primaire et secondaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: German (DE)
Filing Language: German (DE)